Casi Pharmaceuticals (CASI): ROCKVILLE, Md., May 30, 2017

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	0
Posts	463
Boards Moderated	0
Alias Born	04/24/2004

Rocky I

Re: None

Tuesday, 05/30/2017 8:57:28 AM

Tuesday, May 30, 2017 8:57:28 AM

ROCKVILLE, Md., May 30, 2017 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company dedicated to innovative therapeutics addressing cancer and other unmet medical needs announces a poster presentation on ENMD-2076 at the American Society of Clinical Oncology Annual Meeting being held June 2 – 6, 2017 in Chicago. ENMD-2076 is currently in a Phase 2 trial for the treatment of clear cell ovarian carcinoma (CCOC) at Princess Margaret Hospital Centre in Toronto. The poster will be presented in the sessions listed below and will be available on the CASI Pharmaceuticals website afterward.

Gynecologic Cancer:
General Poster Session
Saturday, June 3, 2017, 1:15PM – 4:45PM (CDT)
Abstract No.: 5522, Poster Board No.: 344
Title: Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret Phase 2 consortium
Location: Hall A
Poster Discussion Session
Saturday, June 3, 2017, 4:45PM – 6:00PM (CDT)
Location: Arie Crown Theater